Benzinga | Oct 6, 2021 08:08AM EDT

Goldman Sachs Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $170

Goldman Sachs analyst Paul Choi maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Buy and raises the price target from $151 to $170.